Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Garmin Ltd. (GRMN) vs Smith & Nephew plc (SNN) Price & Performance

Garmin Ltd.Trade
Smith & Nephew plcTrade

Price performance (Past 24H)

Key statistics

Garmin Ltd. vs Smith & Nephew plc — how do they compare? Garmin Ltd. trades at $250.11 (market cap $46.62B), while Smith & Nephew plc trades at $31.41 (market cap $12.81B). The key difference: Garmin Ltd. is far larger — about 3.6× Smith & Nephew plc's market cap, and Smith & Nephew plc pays the higher dividend (2.54%). Which is the better fit depends on your goals.

GRMNSNN
Market Cap
$46.62B$12.81B
Sector
TechnologyHealth
52-Week High
$267.52$38.70
52-Week Low
$187.10$28.73
Enterprise Value
$44.09B$15.58B
Dividend Yield
1.74%2.54%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Garmin Ltd.

Garmin (GRMN) trades at $247.96, up 2.72% on the day, with a neutral technical outlook and mixed earnings history including recent beats. Revenue growth is strong, reaching $7.25B in 2025, with robust profitability margins. Recent news highlights product innovations in aviation and marine electronics, supporting growth prospects. The stock is near its consensus price target of $281.50, indicating moderate upside potential from current levels.

The outlook for GRMN is cautiously optimistic, driven by solid fundamentals and innovation, but tempered by high valuation ratios and a majority hold rating from analysts. Key risks include competitive pressures and market volatility, while institutional sentiment remains mixed with limited insider activity noted.

Smith & Nephew plc

Smith & Nephew (SNN) trades at $31.41, up 5.28% today, with a bullish technical signal from moving averages. The company shows improving fundamentals with revenue growth from $5.8B in 2024 to $6.2B projected for 2025 and net income margin expanding to 10.14%. Recent product launches in robotics and wound care, plus a $500M share buyback, highlight strategic execution. Analyst consensus is mixed with 27% buy ratings but 68% hold, reflecting cautious optimism amid earnings volatility where two of the last four quarters missed expectations.

Outlook: SNN's recovery trajectory and product innovation support long-term growth, but investor patience is needed due to earnings inconsistency and moderate debt levels. Key risks include competitive pressures in medtech and execution on guidance. The stock presents a value opportunity if operational improvements continue, trading at reasonable valuations (P/E 21.5, P/S 2.18) versus sector peers.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Garmin Ltd.

Garmin produces GPS-enabled hardware and software for five verticals: fitness, outdoors, auto, aviation, and marine. The company relies on licensing mapping data to enable its hardware specialized for often niche activities like scuba diving or sailing. Garmin operates in 100 countries and sells its products via distributors as well as relationships with original equipment manufacturers.

Read more on GRMN

About Smith & Nephew plc

Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.

Read more on SNN